3 ways Kennedy’s MAHA vision on chronic disease will be tested in 2026

3 2 minutes read

In 2025, chronic diseases took the spotlight in America, with Health Secretary Robert F. Kennedy Jr. making significant strides in combating these enduring ailments. The Trump administration established a commission focused on childhood chronic illnesses, leading to the issuance of two impactful reports. Make America Healthy Again-inspired legislation was passed in statehouses nationwide, and both private companies and public bodies began prioritizing efforts to combat disease. Additionally, Supplemental Nutritional Assistance Programs removed soda from their menus in a bid to promote healthier eating habits.

Despite these efforts, the root causes of chronic diseases affecting millions of Americans remain largely unchanged, if not exacerbated. The administration’s initial actions included cuts to scientific research and public health expertise, while Congress reduced benefits supporting the health of low-income individuals, including children. The MAHA commission, led by Kennedy, made promises that have yet to be fully realized or diluted.

Kennedy’s most notable achievement in 2025 was the significant overhaul of federal vaccine policy to align with his beliefs, introducing skepticism into the highest echelons of government. However, concerns were raised following a press conference discussing an alleged link between Tylenol and autism.

Looking ahead to 2026, three key issues are poised to further shape Kennedy’s legacy and potentially have a positive impact on chronic disease:

GLP-1 Price Drops: The decreasing prices of GLP-1 drugs like Ozempic, Wegovy, and Zepbound are expected to have a profound effect on public health. These medications have shown promise in inducing weight loss and reducing cardiovascular risk, addressing prevalent conditions like obesity and type 2 diabetes. The potential benefits of GLP-1s extend to treating substance use disorders, particularly alcohol abuse, which can lead to various chronic conditions. However, further research is needed to fully understand the long-term safety and side effects of these drugs.
New Dietary Guidelines: Anticipation surrounds the upcoming dietary guidelines, particularly regarding saturated fat and ultra-processed foods. Kennedy aims to overturn current recommendations limiting saturated fat intake, a move that could impact industries like meat and dairy. The guidelines may also address concerns around ultra-processed foods, with potential implications for school meal programs and military cafeterias. The guidelines are expected to emphasize prevention and chronic disease management through dietary choices.
Health-Boosting Experiments in Rural America: The Rural Health Transformation Program, with its substantial budget, aims to address disparities in rural healthcare. States are vying for funding by proposing programs focused on new technologies, prevention, and closer healthcare services for rural residents. Initiatives in states like Montana, New York, Indiana, and Texas highlight efforts to combat chronic diseases and improve overall health outcomes in rural areas.
As we move into 2026, the outcomes of these initiatives will shape the landscape of public health and chronic disease management in America. Kennedy’s legacy hinges on the success of these endeavors and the impact they have on improving the health and well-being of the population.